HJF co-hosted a day of virtual COVID-19 research presentations in collaboration with DoD partners.

A recently released study shows that colon cancer patients in the Military Health System have significantly better survival, compared to general population.

The Washington Business Journal identified HJF as the second largest biosciences employer in the greater Washington D.C. metro area.

HJF received notice of allowance for a patent for a medical countermeasure to organophosphate (OP) exposure, including the deadly chemical weapon Sarin.

This year's Heroes of Military Medicine Honorees all contributed to the fight against COVID-19. Learn more in this article by HJF writer Dave Savold.

This DOD-funded initiative will assess the role of continuous biosensor data and artificial intelligence in addressing the COVID-19 pandemic.

HJF honors the 2021 Heroes of Military Medicine highlighting those involved in the fight against COVID-19.

In addition to the medical advancements borne out of military medical research, HJF prides itself on being conscientious consumers of resources.

NMRC and HJF secure up to $2.5M in agreement with Lumen Bioscience, Inc. to test a low-cost antibiotic alternative.

The exhibition is part of Creative Forces: NEA Military Healing Arts Network. Creative Forces is managed in partnership with Americans for the Arts and HJF.

HJF has more than 200 technologies available for licensing.

HJF supported research center participates in new study titled STORM CHASER to evaluate antibody combination therapy treatment of COVID-19.

The Wall Street Journal wrote an article about research supported by HJF to study blood-purification to treat COVID-19.

Nipah and Hendra viruses vaccine demonstrated effectiveness in preclinical studies as early as seven days following a single immunization.

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) released its FY20 annual report.